Retatrutide uniquely binds to GLP-1, GIP, and glucagon receptors
A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM
Per AgelessRx's terms of use, neither the platform nor the medical groups associated with it are enrolled with Medicare, Medicaid, or private insurance programs
Summary: Ipamorelin 5mg is a synthetic pentapeptide research peptide investigated in laboratory studies for its interaction with growth hormone secretagogue (GHS) receptor signalling pathways involved in endocrine regulation
Use the BMI calculator to ensure you're OVER 25 - then Book a consultation with Katie, Trish, Kristen, Christine, or Michelle
No long-term safety data from controlled clinical trials exists